Jamile M Shammo
Jamile M Shammo
Maria M Aleman
Maria M Aleman
John S Waye,Landry E Nfonsam
John S Waye
Julie R Boiko,Paul A Carpenter
Julie R Boiko
Retinal imaging and supervised learning predict hospitalizations, kidney, and heart-lung damage in sickle cell disease [0.03%]
视网膜影像和有监督学习预测镰状细胞疾病患者的住院率、肾脏损伤及心肺损害
Sarah McCuskee,Zelong Liu,Hao-Chih Lee et al.
Sarah McCuskee et al.
Sickle cell disease (SCD) is a single-gene illness which causes painful vaso-occlusion, debilitating organ damage, and early mortality. Its clinical course is variable, but current prognostic tools have large data requirements. Understandin...
The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study [0.03%]
用于骨髓纤维化的赖氨酸特异性去甲基化酶1(LSD1)抑制剂博美他司：一项I/II期临床研究的结果
Harinder Gill,Abdulraheem Yacoub,Aaron T Gerds et al.
Harinder Gill et al.
Novel therapies for myelofibrosis (MF) are needed, particularly after JAK inhibitor failure. This open-label, phase 1/2 study evaluated bomedemstat, an irreversible inhibitor of lysine-specific demethylase 1 (LSD1), in participants with MF ...
TCRVβ-targeting antibody-drug conjugates as a novel strategy to eliminate malignant T cells in T cell cancers [0.03%]
靶向TCRVβ抗体-药物偶联物可消除T细胞恶性肿瘤中的恶性T细胞是一项新策略
Chella Krishna Vadivel,Kirstine Sandal Nørregaard,Alba Martínez Perlado et al.
Chella Krishna Vadivel et al.
Cutaneous T cell lymphomas (CTCL) are heterogeneous non-Hodgkin hematolymphoid malignancies characterized by clonal T cell receptors (TCR), which serve as diagnostic hallmarks and potential therapeutic targets. Advanced CTCL remains difficu...
Jose F Camargo
Jose F Camargo
Prevalence, incidence, and risk factors of secondary malignancies in patients with polycythemia vera: A real-world study [0.03%]
真性红细胞增多症患者的继发性恶性肿瘤的患病率、发病风险及危险因素：一项真实世界研究
Naveen Pemmaraju,Alina Markova,Lucia Masarova et al.
Naveen Pemmaraju et al.
Patients with the primary myeloproliferative neoplasm polycythemia vera (PV) are at risk of the development of secondary malignancies, including skin cancers. This real-world, retrospective cohort study used Optum Market Clarity electronic ...
Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC study [0.03%]
EPIC研究：伊布替尼一线治疗CLL患者的3年真实世界随访数据
Toby A Eyre,Nicolás Martínez-Calle,Shankara Paneesha et al.
Toby A Eyre et al.
Clinical trials indicate that acalabrutinib, a second-generation Bruton tyrosine kinase inhibitor, is safe and effective for treating patients with chronic lymphocytic leukemia (CLL), but real-world evidence on its clinical effectiveness is...